CN1264821C - 氨基苯氧基乙酰胺衍生物和含有它们的药物组合物 - Google Patents

氨基苯氧基乙酰胺衍生物和含有它们的药物组合物 Download PDF

Info

Publication number
CN1264821C
CN1264821C CNB018009085A CN01800908A CN1264821C CN 1264821 C CN1264821 C CN 1264821C CN B018009085 A CNB018009085 A CN B018009085A CN 01800908 A CN01800908 A CN 01800908A CN 1264821 C CN1264821 C CN 1264821C
Authority
CN
China
Prior art keywords
group
compound
brain
aminophenoxyacetamide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018009085A
Other languages
English (en)
Chinese (zh)
Other versions
CN1449493A (zh
Inventor
竹本尚弘
案浦洋一
村山宣人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
Original Assignee
Daiichi Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Asubio Pharma Co Ltd filed Critical Daiichi Asubio Pharma Co Ltd
Publication of CN1449493A publication Critical patent/CN1449493A/zh
Application granted granted Critical
Publication of CN1264821C publication Critical patent/CN1264821C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB018009085A 2000-04-13 2001-04-13 氨基苯氧基乙酰胺衍生物和含有它们的药物组合物 Expired - Fee Related CN1264821C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000112100 2000-04-13
JP112100/00 2000-04-13
JP112100/2000 2000-04-13

Publications (2)

Publication Number Publication Date
CN1449493A CN1449493A (zh) 2003-10-15
CN1264821C true CN1264821C (zh) 2006-07-19

Family

ID=18624324

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018009085A Expired - Fee Related CN1264821C (zh) 2000-04-13 2001-04-13 氨基苯氧基乙酰胺衍生物和含有它们的药物组合物

Country Status (12)

Country Link
US (2) US7067533B2 (enExample)
EP (1) EP1228367B1 (enExample)
JP (1) JP2004501079A (enExample)
KR (1) KR100853968B1 (enExample)
CN (1) CN1264821C (enExample)
AT (1) ATE374366T1 (enExample)
AU (1) AU784930B2 (enExample)
CA (1) CA2370487A1 (enExample)
DE (1) DE60130628T2 (enExample)
ES (1) ES2291308T3 (enExample)
HU (1) HUP0203383A3 (enExample)
WO (1) WO2001079170A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
JP2005508907A (ja) * 2001-09-14 2005-04-07 ノボ　ノルディスク　アクティーゼルスカブ ヒスタミンｈ３受容体に選択的に結合する置換されたピペリジン
AU2006333522A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
DE102005062990A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
SI2151439T1 (sl) * 2007-04-27 2014-05-30 Daiichi Sankyo Company, Limited Nitrogeniran aromatski derivat s 6-členskim obročem in farmacevtsko sredstvo, ki obsega ta derivat
US20180305334A1 (en) * 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
KR20190015748A (ko) 2016-06-08 2019-02-14 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Atf4 경로 억제제로서의 화학적 화합물
CN111285820A (zh) * 2018-12-07 2020-06-16 成都康弘药业集团股份有限公司 一种枸橼酸莫沙必利有关物质及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW204411B (enExample) * 1991-06-05 1993-04-21 Tokyo Electron Co Ltd
EP0982026B1 (en) 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
CN1198613C (zh) 1998-10-16 2005-04-27 第一三得利制药株式会社 氨基苯氧基乙酸衍生物和含有它们的药用组合物

Also Published As

Publication number Publication date
DE60130628T2 (de) 2008-07-10
HUP0203383A3 (en) 2003-11-28
DE60130628D1 (de) 2007-11-08
US7067533B2 (en) 2006-06-27
ATE374366T1 (de) 2007-10-15
US20060178401A1 (en) 2006-08-10
ES2291308T3 (es) 2008-03-01
KR20020016830A (ko) 2002-03-06
AU784930B2 (en) 2006-08-03
US20030139447A1 (en) 2003-07-24
WO2001079170A3 (en) 2002-06-13
CN1449493A (zh) 2003-10-15
CA2370487A1 (en) 2001-10-25
AU4876201A (en) 2001-10-30
KR100853968B1 (ko) 2008-08-25
EP1228367A2 (en) 2002-08-07
HUP0203383A2 (hu) 2003-02-28
WO2001079170A2 (en) 2001-10-25
JP2004501079A (ja) 2004-01-15
EP1228367B1 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
CN1198613C (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1135982C (zh) 含n-酰基-2,3-苯并二氮杂�衍生物的药物组合物的制备方法
CN1078889C (zh) 非肽类速激肽受体拮抗剂
CN1231468C (zh) 化合物
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1056605C (zh) 作为人速激肽ⅲ受体的选择性拮抗剂的化合物及其用途
CN1229351C (zh) 杂环化合物和治疗心力衰竭及其它疾病的方法
CN1192773C (zh) 环胺ccr3拮抗剂
CN1474810A (zh) 取代脲,神经肽yy5受体拮抗剂
CN1270585A (zh) 取代的1,2,3,4－四氢化萘衍生物
CN1871225A (zh) 用作钙通道阻断剂的哌嗪取代化合物
CN1195519C (zh) 5－HT再摄取抑制剂与h5－HT1B拮抗剂或部分激动剂的组合物
CN1476434A (zh) 新化合物
CN1500081A (zh) 乙内酰硫脲及其在治疗糖尿病方面的用途
CN1575169A (zh) 用于治疗肥胖的mch拮抗剂
CN1237978A (zh) N－(芳基/杂芳基)氨基酸衍生物、包括这些衍生物的药用组合物以及用这些化合物抑制β－淀粉样肽释放和或其合成的方法
HK1044337A1 (en) Amide compounds
CN101035783A (zh) 作为钙通道阻断剂的脲衍生物
CN1535264A (zh) 精氨酸衍生物
CN1147248A (zh) N-(3-吡咯烷基)苯甲酰胺衍生物
CN1154483C (zh) 胺化合物用于制备阻止肿瘤细胞增殖的药物
CN1976920A (zh) N－型钙通道阻断剂
CN1264821C (zh) 氨基苯氧基乙酰胺衍生物和含有它们的药物组合物
CN1246110A (zh) 芳基哌啶子基丙醇和芳基哌嗪子基丙醇衍生物和含有它们的药物
CN1138853A (zh) 1，5-苯并二氮杂䓬衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: SUNTORY LTD

Effective date: 20051216

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20051216

Address after: Tokyo, Japan, Japan

Applicant after: Daiichi Asubio Pharma Co., Ltd.

Address before: Tokyo, Japan, Japan

Applicant before: Daiichi Suntory Pharma Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ASTERIX PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME OR ADDRESS: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD.

CP03 Change of name, title or address

Address after: Tokyo, Japan

Patentee after: Asubio Pharma Co., Ltd.

Address before: Tokyo, Japan, Japan

Patentee before: Daiichi Asubio Pharma Co., Ltd.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060719

Termination date: 20100413